Publication date: November 2014 | Version: 7 | Pages: 455
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 250 links to online copies of actual companion diagnostics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of companion diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostics dealmaking since 2009 focusing on big pharma and most active of all biopharma, including details of average headline, upfront, milestone and royalty terms by year starting from 2009 to September 2014.
Chapter 3 provides a review of the leading companion diagnostics deals since 2009. Deals are listed by headline value and signed by big pharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies where companion diagnostic deals are available followed by a brief summary. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since January 2009. The chapter is organized by companion diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostics partnering and dealmaking since 2009. The Appendix toward the end includes all the companion diagnostics deals since 2009 by company A-Z, deal type and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes appendices that includes a comprehensive and detailed review of companion diagnostics partnering deals by company A-Z, deal type and soecific therapy focus.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostics technologies and products.
Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide.
Companion Diagnostics Partnering Terms and Agreements includes:
o Trends in companion diagnostics dealmaking in the biopharma industry since 2009
o Analysis of companion diagnostics deal structure
o Access to headline, upfront, milestone and royalty data
o Case studies of real-life companion diagnostics deals
o Access to companion diagnostics contract documents
o The leading companion diagnostics deals by value since 2009
o Most active companion diagnostics dealmakers since 2009
o The leading companion diagnostics partnering resources
In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by:
o Company A-Z
o Headline value
o Stage of development at signing
o Deal component type
o Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 250 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following:
o What are the precise companion diagnostics rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
Chapter 1 – Introduction
Chapter 2 – Trends in companion diagnostics dealmaking
2.2. Companion diagnostics partnering over the years
2.3. Big pharma companion diagnostics dealmaking activity
2.4. Most active companion diagnostics dealmakers
2.5. Companion diagnostics partnering by deal type
2.6. Companion diagnostics partnering by disease type
2.7 Average deal terms for companion diagnostics
2.7.1 Companion diagnostics headline values
2.7.2 Companion diagnostics upfront payments
2.7.3 Companion diagnostics milestone payments
2.7.4 Companion diagnostics royalty rates
2.8. The anatomy of companion diagnostics partnering
Chapter 3 – Leading companion diagnostics deals
3.2. Companion diagnostics deals by value
3.3. Top companion diagnostics deals involving big pharma
Chapter 4 – Big pharma companion diagnostics deals
4.2. How to use big pharma companion diagnostics partnering deals
4.3. Big pharma companion diagnostics partnering company profiles
Johnson & Johnson
Merck & Co
Chapter 5 – Companion diagnostics contracts dealmaking directory
5.2. Companion Diagnostics deals by company A-Z with contracts
5.3. Companion Diagnostics deals by deal type with contracts
5.4. Companion Diagnostics deals by therapy area with contracts
Chapter 6 – Companion diagnostics dealmaking by technology type
Chapter 7 – Companion diagnostics partnering resource center
7.1. Online companion diagnostics partnering
7.2. Companion diagnostics partnering events
7.3. Further reading on companion diagnostics dealmaking
7.4. Deal type definitions
Appendix 1 – Companion Diagnostics deals by company A-Z
Advanced Biological Laboratories
Akili Interactive Labs
Albert Einstein College of Medicine
Astellas Pharma US
Australian Research Council
Banner Sun Health Research Institute (BSHRI)
BC Cancer Agency
California NanoSystems Institute (CNSI)
Cancer Research Technology
Cancer Research UK
Case Western Reserve University
Cedars-Sinai Medical Center
Cell Signaling Technology
Centre for Imaging Technology Commercialization
Centre National de la Recherche Scientifique
Clinical Reference Laboratory
Columbia University Medical Center
Companion Dx Reference Lab
Dalton Pharma Services
Dana-Farber Cancer Institute
Department of Defense
Enlyten Medical Technologies
European Union Regional Development Fund
Fox Chase Cancer Center
French National Research Agency
Geisinger Health System
German Cancer Research Center
Health Diagnostic Laboratory
Hoffmann La Roche
Hospices Civils de Lyon
Hospital del Mar
HTG Molecular Diagnostics
International Cancer Genome Consortium
Janssen Pharmaceutica NV
Johns Hopkins University
Johnson & Johnson Innovation
Laboratory Corporation of America
Lehigh Valley Health Network
Life Technologies Corporation
Massachusetts General Hospital
Massachusetts Institute of Technology
Max Planck Institute for Infection Biology
MD Anderson Cancer Center
Medco Health Solutions
Memorial Sloan Kettering Cancer Center
Merck and Co
Michael J Fox Foundation
Montefiore Medical Center
National Cancer Institute
National Center for Drug Screening
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
National Research Council Canada
National Science Foundation
Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBEREHD)
New Liberty Proteomics
New York University
Nicholas Conor Institute for Pediatric Cancer Research
Ontario Cancer Biomarker Network
Ontario Institute for Cancer Research
Oxford Gene Technology
Peking University Cancer Hospital
Penn State Hershey
Personal Genome Diagnostics
QIAGEN (Suzhou) Translational Medicine Center
Research Institute of the Hospital Universitari Vall d'Hebron
Roche Molecular Systems
Rush University Medical Center
Samsung Medical Center
Seoul National University
Shanghai Pharmaceuticals Holdings
Siemens Healthcare Diagnostics
Small Business Innovation Research
Smart Personalized Medicine
Sunnybrook Health Sciences Centre
Technology Strategy Board (UK)
The Fleury Group
Thermo Fisher Scientific
United Kingdom Critical Care Genomics
University College London
University Health Network
University of Barcelona
University of Bonn
University of California, San Diego
University of California Los Angeles
University of Central Florida Research Foundation
University of Colorado Denver
University of Minnesota
University of North Texas Health Science Center
University of Pennsylvania
University of Pennsylvania School of Veterinary Medicine
University of Pittsburgh Cancer Institute
Ventana Medical Systems
Wake Forest University School of Medicine
Appendix 2 – Companion Diagnostics deals by deal type
Appendix 3– Companion Diagnostics deals by therapy type
Central Nervous System
About Wildwood Ventures
Recent titles from Current Partnering
Order Form – Upgrades to subscription access products
Order Form – Technology Reports
Order Form – Therapy Reports
Table of figures
Figure 1: Companion diagnostics partnering since 2009
Figure 2: Big pharma – top 50 – companion diagnostics deals 2009 to 2014
Figure 3: Big pharma companion diagnostics deal frequency – 2009 to 2014
Figure 4: Active companion diagnostics dealmaking activity– 2009 to 2014
Figure 5: Companion diagnostics partnering by deal type since 2009
Figure 6: Companion diagnostics partnering by disease type since 2009
Figure 7: Companion diagnostics partnering by oncology target since 2009
Figure 8: Companion diagnostics deals with a headline value by year- 2014
Figure 9: Companion diagnostics deals with a headline value by year- 2013
Figure 10: Companion diagnostics deals with a headline value by year- 2012
Figure 11: Companion diagnostics deals with a headline value by year- 2011
Figure 12: Companion diagnostics deals with a headline value by year- 2010
Figure 13: Companion diagnostics deals with a headline value by year- 2009
Figure 14: Summary median headline value by year, 2009-2014
Figure 15: Companion diagnostics deals with an upfront value by year- 2014
Figure 16: Companion diagnostics deals with an upfront value by year- 2013
Figure 17: Companion diagnostics deals with an upfront value by year- 2012
Figure 18: Companion diagnostics deals with an upfront value by year- 2011
Figure 19: Companion diagnostics deals with an upfront value by year- 2010
Figure 20: Companion diagnostics deals with an upfront value by year- 2009
Figure 21: Summary median upfront value by year, 2009-2014
Figure 22: Companion diagnostics deals with a milestone value by year- 2014
Figure 23: Companion diagnostics deals with a milestone value by year- 2013
Figure 24: Companion diagnostics deals with a milestone value by year- 2012
Figure 25: Companion diagnostics deals with a milestone value by year- 2011
Figure 26: Companion diagnostics deals with a milestone value by year- 2010
Figure 27: Companion diagnostics deals with a milestone value by year- 2009
Figure 28: Companion diagnostics deals with a royalty rate by year- 2014
Figure 29: Companion diagnostics deals with a royalty rate by year- 2013
Figure 30: Companion diagnostics deals with a royalty rate by year- 2012
Figure 31: Companion diagnostics deals with a royalty rate by year- 2011
Figure 32: Companion diagnostics deals with a royalty rate by year- 2010
Figure 33: Companion diagnostics deals with a royalty rate by year- 2009
Figure 34: Summary median royalty rate by year, 2009-2014
Figure 35: Components of the typical companion diagnostics deal structure
Figure 36: Top companion diagnostics deals by value since 2009
Figure 37: Top companion diagnostics deals signed by big pharma value since 2009
Figure 38: Online partnering resources
Figure 39: Forthcoming partnering events